FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
The reach of the Indian pharmaceutical industry is enormous. India supplies a large and increasing amount of the generic drugs sold globally, and the country is home to over 150 drug manufacturing facilities approved by the US Food and Drug Administration1—including many run by multinational players.
The basic challenge faced by medical products companies is that they’re trying to sell expensive products into an environment that’s increasing concerned about the cost of care, and in which key stakeholders are aggressively looking for opportunities to bring the costs down, and avoid unnecessary expenditures.
FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.
As drug companies take divergent strategies focused either on research or cutting costs, what might this mean for the path future companies take in the pharmaceutical industry?
High-profile technology companies are revered by society while pharmaceutical companies developing life-saving technologies are viewed with contempt; why the disparity?
The tragic deaths of 55 Americans and sickening of more than 740, resulting from contaminated steroid injections that were shipped by a disreputable firm in Massachusetts, have rightly focused public attention on a largely unfamiliar, but prominent part of our drug supply chain – the practice of pharmacy compounding.
Scott Gottlieb's testimony for the House Energy and Commerce Committee, Subcommittee on Health's hearing on drug compounding.
In this conference, veterans of the Iraq and Afghanistan wars, mental health and disability experts, and an economist will discuss current hurdles to rehabilitation, and suggest alternatives that could more effectively expedite the reintegration of veterans into their families, communities, and workplaces.
Please join Representative Randy Forbes (R-VA), AEI, the Heritage Foundation, and the Foreign Policy Initiative for a timely discussion on the 2014 QDR and the future of American defense strategy in an era of constrained budgets.
This event is livestream only.
AEI’s Philanthropic Freedom Project welcomes Bill Gates for an exclusive event at AEI.